Nitazenes in the UK: What Police Leaders Need to Know

Nitazenes are already a serious UK drug threat. The latest national evidence, however, is more complicated than the idea that synthetic opioids are simply replacing heroin.

The National Crime Agency’s 2026 assessment says the UK heroin market remained broadly stable in 2025, despite continued uncertainty following the Taliban’s opium ban. At the same time, the NCA assesses that suppliers are highly likely to continue fortifying heroin and illicit pharmaceutical drugs with synthetic opioids, often without users knowing what is present. NCA National Strategic Assessment 2026.

That distinction changes the policing problem. The threat is not only a new drug replacing an old one. It is a potent substance entering existing markets in ways that make ordinary assumptions about what somebody has taken less reliable.

The NCA recorded 359 nitazene-related deaths in the UK in 2025, down from 435 in 2024, with the cumulative recorded total close to 1,000 since June 2023. It cautions that the 2025 figure is expected to increase as further testing is completed. NCA, 2026.

A falling annual count is therefore welcome, but it is not evidence that the threat has gone away.

The risk sits inside several drug markets

Government guidance warns that potent synthetic opioids can appear in heroin, counterfeit opioid tablets and, less commonly, other drugs including cocaine, benzodiazepines and synthetic cannabinoids. OHID guidance.

That widens the population at risk. A person who knowingly uses heroin may recognise opioid overdose and be connected to treatment or naloxone provision. Someone who believes they have bought a benzodiazepine or another drug may have neither tolerance nor any reason to expect an opioid effect.

For policing, this means scene information matters. A cluster of apparently unrelated collapses may be connected by a batch, supplier, online marketplace or county line rather than by the drug people thought they were buying.

Naloxone is a preparedness issue, not a specialist extra

Naloxone is the emergency antidote for overdose caused by opioids including nitazenes. Current government guidance states that standard repeated dosing should be used until breathing is restored and ambulance care arrives. OHID guidance.

The Home Office’s review of local preparedness goes further. It recommends that local areas include naloxone supply in their needs assessments, know how stock will be purchased and distributed, and test incident plans with relevant partners. Home Office, Local preparedness for synthetic opioids in England.

The government has also widened the routes through which take-home naloxone can be supplied without a prescription. Department of Health and Social Care.

The operational question for a chief officer is therefore not whether naloxone is a health intervention. It is whether officers likely to encounter overdose know how to recognise respiratory depression, can summon medical help quickly and can administer naloxone where force policy provides for it. Where treatment sits in the wider picture — and why opioid substitution treatment carries some of the strongest evidence anywhere in drug policy — is set out in Drug policy: where the evidence is strong, and where it is not.

The useful warning signs arrive before the death count

A local synthetic-opioid response should not depend on waiting for confirmed fatalities. Toxicology takes time and deaths are a lagging indicator.

The national preparedness framework instead points to a combination of signals: unusual non-fatal overdoses, increased naloxone use, drug-seizure analysis, treatment-service intelligence, ambulance data, drug-checking results and information from policing. Home Office, 2025.

The West Midlands experience is important because government explicitly used it to develop the preparedness model. A cluster in 2023 led to a structured debrief using emergency-preparedness principles, and subsequent national exercises tested how local systems would respond to contaminated heroin, counterfeit medicines, public events and other scenarios.

This is not ordinary drugs intelligence with a new substance added. It is a local resilience problem involving policing, public health, ambulance trusts, treatment services, laboratories, communications teams and national agencies.

What police leaders should require

Every force should be able to answer four questions.

Who receives the warning when a local drug information system detects an unusual pattern? Who has authority to escalate the response out of hours? What information can policing contribute quickly from seizures, scenes and supply networks? And what is the route for getting a public warning to the right population without waiting for certainty that arrives too late?

Combating Drugs Partnerships should test those arrangements with the same people who would have to run them during a real incident. The Home Office guidance specifically recommends rehearsed plans, defined responsibilities, naloxone assurance and links to established law-enforcement protocols. Home Office, 2025.

The current evidence does not justify saying Britain has already undergone a North American-style synthetic-opioid transition. It does justify preparing for potent opioids to appear unpredictably inside existing drug markets.

That is a narrower conclusion than the earlier version of this article. It is also more useful. The leadership task is to build a system that can recognise an unusual cluster, warn people, save lives and trace the supply before the pattern becomes obvious in the mortality statistics.

---

Sources and further reading

• National Crime Agency — National Strategic Assessment 2026: harm to individuals.
• National Crime Agency — how threats changed in 2025.
• Home Office — Local preparedness for synthetic opioids in England.
• OHID — Guidance for local areas on planning to deal with potent synthetic opioids.
• Department of Health and Social Care — Supplying take-home naloxone without a prescription.